News
Teleperformance Strengthens Its Governance to Accelerate Its Growth and Prepare for the Future
Regulatory News:
Teleperformance (Paris:TEP), a global leader in digital business services, announced today significant changes to its governance in order to accelerate its growth and foster
Freelance.com: 2nd quarter 2024 revenue: €258.8m (+23%)
Eutelsat and Cable Color Renew Multi-year Agreement for Broadcast Services in Latin America
Eutelsat Group (ISIN: FR0010221234 - Euronext Paris / London Stock Exchange: ETL) and Honduras’s Cable Color LLC have signed a new multi-year agreement renewing capacity for video broadcast
PULLUP ENTERTAINMENT: Results of employee share ownership plan
United Group Consolidates Broadcasting Activities on Eutelsat’s Major European Direct-To-Home Positions, EUTELSAT 16A and HOTBIRD, to Maximise Audience Reach
Regulatory News:
Eutelsat Group (ISIN: FR0010221234 – Euronext Paris / London Stock Exchange: ETL) announces that it has been selected by United Group, South-East Europe’s leading provider of
Ace Hardware Selects VusionGroup’s Innovative Solutions to Enhance Retail Experience
VusionGroup (VU - FR0010282822) announced today a new partnership with Ace Hardware to integrate their advanced digital shelf label (DSL) technology across Ace Hardware stores. Amongst the first
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan
Regulatory News:
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) and POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
Sensorion Announces its Participation in Stifel's Biotech Summer Summit
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Teleperformance SE: First-Half 2024 Results
Regulatory News:
The Board of Directors of Teleperformance, a leading global group in digital business services, met today and reviewed the consolidated financial statements for the six months
Kaufman & Broad SA: AVAILABILITY OF THE 2024 HALF YEARLY INTERIM FINANCIAL REPORT
Bureau Veritas: Early Impact of the New LEAP | 28 Strategy Boosting Revenue and Improving Margins1 in the First Half; 2024 Revenue Outlook Upgraded
Hinda Gharbi, Chief Executive Officer, commented
“In the first half of the year, we kick started the execution of our LEAP I 28 strategy which was launched at the end of March 2024. Our H1 results
Bureau Veritas Acquires Security Innovation Inc. to Reinforce Its Cybersecurity Expertise in the Software Domain
Bureau Veritas, a global leader in the Testing, Inspection and Certification (TIC) industry, announces today it has signed an agreement to acquire Security Innovation Inc., a US-based specialized
Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of
ASICS and Dassault Systèmes Demonstrate On-Demand, Personalized Footwear
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and ASICS have jointly opened a studio in Paris to test a new service providing on-demand sockliners personalized for individual foot shape
Prodware: Revenue Triples in H1 2024: €315.7 M (+191.4%)
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Kaufman & Broad SA: IMPLEMENTATION OF THE SHARE BUY-BACK PROGRAM
Sartorius Stedim Biotech SA: Information on Document Availability
Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) reports today its business indicators for the first half of 2024, provide an update on